about
Children's Oncology Group's 2013 blueprint for research: bone tumorsInsulin-like growth factor system in cancer: novel targeted therapiesDual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategyR1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyA Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium ReportEwing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions.Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachTargeted Therapy of Ewing's Sarcoma.Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell linesNovel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma.Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data.Protein kinase Cδ promotes proliferation and induces malignant transformation in skeletal muscleIGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.Cancer cell signaling pathways targeted by spice-derived nutraceuticals.A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma.Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group studyMolecular and cellular biology of rhabdomyosarcoma.CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling.Past, present and future of therapies in pediatric sarcomas.PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.Expression characteristics of proteins of IGF-1R, p-Akt, and survivin in papillary thyroid carcinoma patients with type 2 diabetes mellitus.Emerging drugs for high-grade osteosarcoma.Caveolins in rhabdomyosarcomaRhabdomyosarcomas: an overview on the experimental animal models.Preclinical drug development for childhood cancer.Current and future management strategies for relapsed or progressive hepatoblastoma.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing's sarcoma A673-xenograft growth and normalize tumor vascular architecture.18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models.MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions.Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.
P2860
Q27027664-087595C1-6BC2-42E9-87E1-61B028014EE7Q28081603-DD0406D2-81AB-477B-9DD2-CFDCB09F11B6Q30540343-6403855A-B692-4FA9-A439-F6661250A992Q33397796-F87A53E2-6C7A-4B6F-82F2-F686799FAE9CQ33419115-9E93330E-2BD1-42F4-B2CF-24E7350073D0Q33861072-92EF505C-584C-48E1-9254-DBF959A2C7A4Q33890792-7F99B315-653D-4415-A275-5FFA859A348AQ33925323-A5FD36E6-6235-464F-93DF-8388A8349896Q34262377-0D09E0A2-E1C5-4257-996B-A7F19FA20BA3Q34406479-4EDF4C76-7D05-4F8F-9974-18EF5182B126Q34442835-34699175-F874-4CFC-A868-78101DB586E5Q34683782-4BE3B603-C903-4CF0-B971-99D88132E0B0Q35511058-54D8310E-6584-4EEE-91B2-4B3E87EEE845Q35531322-67E66A7A-D5D9-4320-9C0A-9C71D59934F1Q35555492-C81FA395-3F24-4682-ACFB-078D011C7A31Q35606589-9C07517D-A4D7-45E3-A969-5C4E0B00E084Q36665931-7AB65533-B931-4501-B08A-DDB9BA40E9A7Q36819371-6D414525-7B8E-4E99-A240-06BE8AA920DCQ37162205-DA1F45D4-8724-4BE7-AE57-D8C22FDFCC28Q37385234-616ACB95-D416-4032-81E3-2C49EE1162C7Q37397276-E35C1D7F-902C-44AC-B3C8-6D4A230FCCA7Q37624249-1C55FF6B-31EF-4E4A-8CD1-E39C4BB68A74Q37630588-A293D8E8-5472-42A9-A41A-19458096DC6DQ37694869-6D857359-E1ED-412F-9D7A-F2C42CA93102Q37725915-EAFDF2C8-4284-4C8B-B835-B519E1B0B2C4Q37727180-5EB4AFA7-A912-4C77-807E-012A6C50E29FQ37727258-1AC6CFE4-5C44-4B30-870C-A7459E8EEFC3Q37778400-6A0DA141-4527-498F-A9F3-47B37A43005CQ37894860-124CFBC0-CC76-460E-8EA8-67E094C3E6D9Q37973827-7A5A7E89-3BDD-4AE1-A085-21E555C7770EQ38014543-16C2BFA7-2EDE-4673-BA3E-74D3B431B2DAQ38019027-6A9EEE63-C9A8-47BB-BDE2-CC1BA291E62EQ38113988-0D3D533F-6345-47E3-8609-FA69FEC511D9Q38334606-AA3683A9-DAED-4660-B3D2-BF55167F4521Q38682244-DCF133C6-9194-4CFB-A198-D160EDA449E9Q39292783-9A20C319-47B5-4D35-876B-7183441FA807Q39413508-66D56764-289F-4097-A925-C5C06665F4B0Q39618772-E7ED7C62-2DF5-4167-B5B8-684F00055E40Q39624408-3398D4A4-6739-4AF9-9E32-2C38AB51CACDQ39639490-5F772309-37A1-4411-AFF1-C7BB67D47DFC
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The role of IGF-1R in pediatric malignancies.
@en
The role of IGF-1R in pediatric malignancies.
@nl
type
label
The role of IGF-1R in pediatric malignancies.
@en
The role of IGF-1R in pediatric malignancies.
@nl
prefLabel
The role of IGF-1R in pediatric malignancies.
@en
The role of IGF-1R in pediatric malignancies.
@nl
P2093
P2860
P1433
P1476
The role of IGF-1R in pediatric malignancies.
@en
P2093
Daniel Scher
Jeffrey A Toretsky
Lee J Helman
Su Young Kim
P2860
P356
10.1634/THEONCOLOGIST.2008-0189
P577
2009-01-06T00:00:00Z